Quick BIO CEO Departure Raises Questions About Direction For Next Leadership Pick

Michelle McMurry-Heath brought a science and regulatory background to the top post of the industry trade group in contrast to the political and lobbying focused careers of her predecessors. Her eventual successor may offer hints as to whether BIO thought that was a successful leadership strategy.

wooden blocks with people
New leadership search offers BIO a chance to once again decide on the type of leader the trade groups wants at the top. • Source: Shutterstock

The Biotechnology Innovation Organization may need to do some soul searching as it commences its search for a new CEO following the resignation of Michelle McMurry-Heath after less than two and half years at the helm of the trade organization which represents a wide variety of biotech and pharmaceutical companies.

McMurry-Heath’s resignation late on 10 October followed media reports just days earlier that she was on leave following disagreements with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

Coping Strategies For China Industry Amid BIOSECURE Overhang

 
• By 

With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."

EU Pharma Reform: What You Need to Know Now

 

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

 
• By 

US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.

US Presidential Elections: Are Prescription Drug Pricing Reforms Losing Political Luster?

 
• By 

Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.

More from Pink Sheet

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.

PinkSheet-R&D-Free: ‘Ranking’ article that includes different Composer content

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.